Cancer immunotherapies market to 2024 increased uptake of immune checkpoint inhibitors driving growth, supported by a large, robust pipeline

1
Cancer Immunotherapies Market to 2024 - Increased
Uptake of Immune Checkpoint Inhibitors Driving
Growth, Supported by a Large, Robust Pipeline

• Published On 01 Jul 2018

E-mail help_at_grandresearchstore.com
2
Report Description
Cancer immunotherapy, which can predominantly be
classed as a form of targeted therapy, drives an
immune response against cancer cells. This may
include stimulating a patients immune system in
a general way or aiding the identification of
specific antigens associated with the
cancer. The interest in cancer immunotherapy
development has been driven by the growing
understanding of the immune system as a hallmark
of cancer pathophysiology, particularly immune
evasion of developing cancer cells. Overall,
3,863 products are being actively developed in
the cancer immunotherapy pipeline, approximately
half of the overall oncology pipeline.
E-mail help_at_grandresearchstore.com
3
Table of content
1 Table of Contents1 Table of Contents 51.1 List
of Tables 71.2 List of Figures 7 2.1 Therapy
Area Introduction 122.2 Overview of Key
Indications and Symptoms 122.2.1 Breast Cancer
13 3 Key Marketed Products 493.1 Overview
493.2 Revlimid (lenalidomide) - Celgene 503.3
Opdivo (nivolumab) - Ono Pharma/Bristol-Myers
Squibb 53
E-mail help_at_grandresearchstore.com
4
Cancer Immunotherapies Market Value
xx
xx
xx
xx
CAGR 14.7 (2018 - 2024)
xx
xx
xx
xx
E-mail help_at_grandresearchstore.com
5
Get in touch
Get in touch
Click here to know more about report
Follow us
1 [phone] (International)
91 8087042414 (Asia)
www.grandresearchstore.com
help_at_grandresearchstore.com